Because of the important role that EGFR plays in many lung adenocarcinomas, several drugs have been developed that specifically target the EGFR pathway, including EGFR-inhibiting antibodies (cetuximab) and small molecule tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib). This evidence concerns the gene EGFR and lung adenocarcinoma.